Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
…, HY Kim, MG León, C Tanasescu, E Nasonov, JL Lan… - The Lancet, 2011 - thelancet.com
Background Systemic lupus erythematosus is a heterogeneous autoimmune disease that is
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-…
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-…
HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
…, M Lin, HP Huang, YL Lin, JL Lan… - Proceedings of the …, 2005 - National Acad Sciences
Allopurinol, a commonly prescribed medication for gout and hyperuricemia, is a frequent
cause of severe cutaneous adverse reactions (SCAR), which include the drug hypersensitivity …
cause of severe cutaneous adverse reactions (SCAR), which include the drug hypersensitivity …
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …
…, SH Lee, HA Chen, YC Chen, SC Hsieh, JL Lan… - The Lancet, 2018 - thelancet.com
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended
for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when …
for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when …
Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
OBJECTIVE: To investigate concentrations of proinflammatory cytokines in the sera and their
mRNA expression in biopsy specimens of evanescent rash and synovitis from patients with …
mRNA expression in biopsy specimens of evanescent rash and synovitis from patients with …
[HTML][HTML] Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy
Introduction The objective of this study was to investigate the effects of tumor necrosis factor
(TNF)-α inhibitors on circulating T helper-type 17 (Th17) cells and Th17-related cytokines in …
(TNF)-α inhibitors on circulating T helper-type 17 (Th17) cells and Th17-related cytokines in …
Dehydroepiandrosterone treatment of women with mild‐to‐moderate systemic lupus erythematosus: A multicenter randomized, double‐blind, placebo‐controlled trial
DM Chang, JL Lan, HY Lin… - Arthritis & Rheumatism …, 2002 - Wiley Online Library
Objective To evaluate the efficacy and tolerability of dehydroepiandrosterone (DHEA) at a
dosage of 200 mg/day in adult women with active systemic lupus erythematosus (SLE). …
dosage of 200 mg/day in adult women with active systemic lupus erythematosus (SLE). …
Association between a history of periodontitis and the risk of rheumatoid arthritis: a nationwide, population-based, case–control study
…, TJ Chen, P Chou, YL Lee, YJ Chou, JL Lan… - Annals of the …, 2013 - ard.bmj.com
Objective To investigate the association between the risk of rheumatoid arthritis (RA) and a
history of periodontitis. Methods This nationwide, population-based, case–control study used …
history of periodontitis. Methods This nationwide, population-based, case–control study used …
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor …
Objective To investigate the kinetics of hepatitis B virus (HBV) viral loads and HBV reactivation
in rheumatoid arthritis (RA) patients undergoing therapy with tumour necrosis factor alpha …
in rheumatoid arthritis (RA) patients undergoing therapy with tumour necrosis factor alpha …
The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck
JP Li, CY Yang, HC Chuang, JL Lan, DY Chen… - Nature …, 2014 - nature.com
JNK pathway-associated phosphatase (JKAP, also known as DUSP22 or JSP-1) is a JNK
activator. The in vivo role of JKAP in immune regulation remains unclear. Here we report that …
activator. The in vivo role of JKAP in immune regulation remains unclear. Here we report that …
Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid …
Objective To evaluate the associations between (1) antidrug antibody (ADAb) and
therapeutic response, (2) ADAb and serum drug trough levels and (3) serum drug levels and …
therapeutic response, (2) ADAb and serum drug trough levels and (3) serum drug levels and …